Table of Contents Table of Contents
Previous Page  890 / 1082 Next Page
Information
Show Menu
Previous Page 890 / 1082 Next Page
Page Background

S874

ESTRO 36 2017

_______________________________________________________________________________________________

(see

flow

chart).

We retrospectively applied this protocol to 88 historical

treatments (May 2011 - January 2015) performed within

our institute to evaluate its effect.

Results

Of 88 treatments in 86 patients, 36 were initially selected

for 3D CBCT in all fractions. From the remaining 52

treatments 25 would have been suitable for 3D CBCT after

comparing and combining 4D and 3D CBCT position

verification (see pie chart).

Conclusion

With use of the in-treatment decision protocol for 3D or

4D position verification, the number of patients having 3D

CBCT for position verification raised from 41% to 69%. This

is not only beneficial for patient comfort, it limits motion

related treatment degradation and it is also increases

treatment capacity. Therefore we propose to use the in-

treatment CBCT information and our decision protocol for

making optimal use of 3D CBCT.

EP-1635 Framework for the evaluation of interplay

effects between respiratory motion and dose

application

A. Von Münchow

1,2

, K. Straub

1

, J. Hofmaier

1,2

, P.

Freislederer

1

, M. Reiner

1

, C. Thieke

1

, M. Söhn

1

, M. Alber

3

,

R. Floca

4

, C. Belka

1

, K. Parodi

2

, F. Kamp

1

1

LMU Munich - Klinikum der Universität München,

Department of Radiation Oncology, Munich, Germany

2

LMU Munich - Faculty of Physics, Department of Medical

Physics, Munich, Germany

3

Heidelberg University Hospital, Department of

Radiation Oncology, Heidelberg, Germany

4

German Cancer Research Center, Software development

for Integrated Diagnostic and Therapy - Department of

Radiology, Heidelberg, Germany

Purpose or Objective

The interplay between respiratory motion of a tumor and

dose delivered by complex techniques like IMRT and VMAT

can potentially lead to undesirable and non-intuitive

deviations from the planned dose distribution. Small field

sizes and fluences used in these advanced therapy

techniques might amplify the dose deviations. We aim at

developing a 4D dose recalculation tool to simulate the

dose distribution for a moving target volume more

precisely. The impact of interplay effects can be

evaluated and compared for different treatment

techniques.

Material and Methods

We developed a workflow combining a Monte Carlo dose

calculation and a dose accumulation based on 4DCT

images and linac log files. Log data from the linac are

retrieved with

Delivery Parameters Log File Convertor for

Integrity™ R3.2

provided by Elekta. The time information

in these log files has a resolution of 0.04 s and is used to

divide the original treatment plan into small time intervals

correlated to the patient’s respiratory phases. All

resulting plan fragments (each corresponding to a certain

4DCT

phase)

are

then

recalculated

using

MCverify/Hyperion V2.4 (research version of Elekta

MONACO 3.2). As a final step the single doses are sorted

and combined to a total dose distribution. Different

respiratory cycles, e.g. changes in the breathing

frequency or pattern, and treatment methods, e.g.

stereotactic treatment or gating, can be simulated and

compared for different treatment techniques. The

handling and accumulation of the different dose fragments

are performed with AVID, a software framework for

radiation therapy data processing developed at

Deutsches

Krebsforschungszentrum

(DKFZ).

For

a

first

demonstration, implementation and verification, the

4DCT of a

Dynamic Thorax Phantom (CIRS)

is used. A 1D-

sinusoidal-rigid-motion with frequency 0.25 Hz and

amplitude 2 cm was set.

Results

A 3D-CRT and an IMRT plan were delivered to the

phantom. Fig. 1 shows the resulting DVHs for the GTV using

the 3D-CRT and the IMRT plan, respectively. In the plots,

two different starting phases are marked (“treatment

starting in inhale” and “treatment starting in exhale

phase”). The DVHs of the 3D-CRT plan remained

unaffected by the respiratory phase shift. Whereas for the

IMRT plan (optimized on a dose of 10Gy) the maximal dose

changed by 0.27 Gy (2.3%) from 11.95 Gy to 11.68 Gy after

the 50% phase shift.

Fig 1: Example for the occurrence of interplay effects:

IMRT plan segment on two CT Phases